RxDoctor Payments DataLook up a doctor →

Arthur Reitman, MD

Interventional Cardiology · Marietta, GANPI 1184692691

Payments from drug & device makers

$275,254in general payments, 2019–2025

Across 704 payments — averaging $390.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$132K
  • Boston Scientific$125K
  • Abiomed$4K
  • Abbott$3K
  • Shockwave Medical, Inc$3K
  • Edwards Lifesciences$2K
  • plus $7K from 34 others
$1,575in research payments, 2019–2025

Across 1 payment — averaging $1575.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$29,47528%
  • Speaking & faculty fees$25,62524%
  • Travel & lodging$22,63421%
  • Food & beverage$27,92226%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$275,254 in reported general payments places this provider in the 85th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$112,067
Medicare patients
271
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$105,138
XareltoRivaroxaban28$36,829
Repatha SureclickEvolocumab51$32,516
EntrestoSacubitril/Valsartan22$31,204
JardianceEmpagliflozin25$26,200
Praluent PenAlirocumab17$15,893
Ranolazine ErRanolazine16$2,456
Metoprolol Succinate131$1,949
Atorvastatin Calcium193$1,760
ClopidogrelClopidogrel Bisulfate122$1,219
Verapamil ErVerapamil Hcl16$1,056
Nebivolol Hcl14$1,056
Rosuvastatin Calcium129$999
Potassium Chloride45$871
Losartan Potassium74$750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$270$105,13889 claims
Johnson & JohnsonXarelto$343$36,82928 claims
NovartisEntresto$446$31,20422 claims
Boehringer IngelheimJardiance$103$26,20025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →